Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

Benzinga · 05/10 11:00
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $35 price target.